Supporting the designation of the month of May as "Lyme and Tick-borne Disease Awareness Month".
Summary
This non-binding House resolution supports awareness month designation. No spending, no regulatory change, no market impact. Not a tradeable event.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Zero financial impact — resolution is non-binding and symbolic.
- 2.No companies, no tickers, no revenue implications.
- 3.Referral to committee is the first and likely only step for this type of legislation.
Market Implications
No market implications. This is a ceremonial bill with zero economic force. Retail investors should ignore.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Veterans SPORT Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Protecting Health Care and Lowering Costs Act of 2025
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.